J. De Langen

419 total citations
18 papers, 159 citations indexed

About

J. De Langen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, J. De Langen has authored 18 papers receiving a total of 159 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in J. De Langen's work include Lung Cancer Treatments and Mutations (10 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Radiomics and Machine Learning in Medical Imaging (5 papers). J. De Langen is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Radiomics and Machine Learning in Medical Imaging (5 papers). J. De Langen collaborates with scholars based in Netherlands, United States and South Korea. J. De Langen's co-authors include Kim Monkhorst, Joachim G.J.V. Aerts, Ferry Lalezari, Paul Baas, Willemijn S.M.E. Theelen, Egbert F. Smit, Sayed M.S. Hashemi, Erik Thunnissen, Anthonie J. van der Wekken and Alexander Drilon and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Annals of Oncology.

In The Last Decade

J. De Langen

18 papers receiving 155 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. De Langen Netherlands 7 124 99 32 28 22 18 159
Masayuki Shirasawa Japan 10 167 1.3× 108 1.1× 16 0.5× 27 1.0× 21 1.0× 25 213
Gee-Chen Chang Taiwan 6 60 0.5× 112 1.1× 29 0.9× 32 1.1× 15 0.7× 12 180
María José Echarri Spain 5 101 0.8× 71 0.7× 26 0.8× 42 1.5× 19 0.9× 7 146
Yujia Chi China 11 110 0.9× 125 1.3× 20 0.6× 41 1.5× 21 1.0× 20 209
Mojca Unk Slovenia 6 134 1.1× 117 1.2× 69 2.2× 24 0.9× 23 1.0× 14 193
Margaux Geier France 8 167 1.3× 150 1.5× 18 0.6× 23 0.8× 17 0.8× 41 220
Ilias Houda Netherlands 6 108 0.9× 80 0.8× 13 0.4× 16 0.6× 16 0.7× 13 141
Silvana Acquafredda Italy 6 159 1.3× 94 0.9× 19 0.6× 42 1.5× 40 1.8× 8 237
Ina Valeria Zurlo Italy 6 105 0.8× 89 0.9× 15 0.5× 36 1.3× 40 1.8× 24 191

Countries citing papers authored by J. De Langen

Since Specialization
Citations

This map shows the geographic impact of J. De Langen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. De Langen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. De Langen more than expected).

Fields of papers citing papers by J. De Langen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. De Langen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. De Langen. The network helps show where J. De Langen may publish in the future.

Co-authorship network of co-authors of J. De Langen

This figure shows the co-authorship network connecting the top 25 collaborators of J. De Langen. A scholar is included among the top collaborators of J. De Langen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. De Langen. J. De Langen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Verkerk, Karin, Laurien J. Zeverijn, Birgit S. Geurts, et al.. (2023). 1392P Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP). Annals of Oncology. 34. S797–S798. 3 indexed citations
2.
Solomon, Benjamin, Alexander Drilon, W. Marston Linehan, et al.. (2023). 1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial. Annals of Oncology. 34. S787–S788. 26 indexed citations
3.
4.
Smit, Jasper N., Geert Kazemier, Chris Dickhoff, et al.. (2022). Detection of Circulating Tumor Cells Using the Attune NxT. International Journal of Molecular Sciences. 24(1). 21–21. 6 indexed citations
5.
Wekken, Anthonie J. van der, Marthe S. Paats, Sayed M.S. Hashemi, et al.. (2021). Interim results of a phase II single arm trial combining afatinib with cetuximab in patients with EGFRex20ins positive NSCLC.. Journal of Clinical Oncology. 39(15_suppl). 9112–9112. 10 indexed citations
6.
Schram, Alison M., Alexander Drilon, Teresa Macarulla, et al.. (2020). A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors.. Journal of Clinical Oncology. 38(15_suppl). TPS3654–TPS3654. 17 indexed citations
7.
Niemeijer, Anna-Larissa N., Daniela E. Oprea‐Lager, Ronald Boellaard, et al.. (2019). P1.04-12 Tumor Uptake and Biodistribution of 89Zr-Labeled Pembrolizumab in Patients with Metastatic Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S443–S443. 2 indexed citations
8.
Dingemans, Anne‐Marie C., et al.. (2019). Chemotherapy in KRAS-mutated chemotherapy naive non-small cell lung cancer patients: A phase III comparing cisplatin-pemetrexed with carboplatin-paclitaxel-bevacizumab: NVALT 22 (NCT02743923).. Journal of Clinical Oncology. 37(15_suppl). TPS9127–TPS9127. 3 indexed citations
9.
Wekken, Anthonie J. van der, Sayed M.S. Hashemi, Robin Cornelissen, et al.. (2018). P2.13-42 Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology. 13(10). S815–S815. 7 indexed citations
10.
Leung, David, J. De Langen, David Raunig, et al.. (2018). Whole body PD-L1 PET in patients with NSCLC and melanoma.. Journal of Clinical Oncology. 36(5_suppl). 139–139. 2 indexed citations
11.
Wekken, Anthonie J. van der, Sayed M.S. Hashemi, Robin Cornelissen, et al.. (2018). Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer. Annals of Oncology. 29. viii524–viii525. 4 indexed citations
12.
Theelen, Willemijn S.M.E., Ferry Lalezari, J. De Langen, et al.. (2018). Randomized phase II study of pembrolizumab after stereotactic body radiotherapy (SBRT) versus pembrolizumab alone in patients with advanced non-small cell lung cancer: The PEMBRO-RT study.. Journal of Clinical Oncology. 36(15_suppl). 9023–9023. 47 indexed citations
13.
Smit, Egbert F., Idris Bahce, O. S. Hoekstra, et al.. (2017). Whole body PD-1 and PD-L1 PET in pts with NSCLC. Annals of Oncology. 28. v464–v464. 3 indexed citations
14.
Langen, J. De, et al.. (2017). Association of tumor and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with response to nivolumab treatment in NSCLC patients. Annals of Oncology. 28. v29–v29. 3 indexed citations
15.
Langen, J. De, Justine L. Kuiper, Erik Thunnissen, et al.. (2017). Trastuzumab and paclitaxel in patients (pts) with EGFR mutated non-small-cell lung cancer (NSCLC) that express HER2 after progression on EGFR TKI treatment.. Journal of Clinical Oncology. 35(15_suppl). 9042–9042. 8 indexed citations
16.
Niemeijer, Anna-Larissa N., Egbert F. Smit, Guus A.M.S. van Dongen, et al.. (2017). Whole body PD-1 and PD-L1 PET with 89Zr-nivolumab and 18F- BMS-986192 in pts with NSCLC.. Journal of Clinical Oncology. 35(15_suppl). e20047–e20047. 10 indexed citations
17.
Niemeijer, Anna-Larissa N., Egbert F. Smit, Guus A.M.S. van Dongen, et al.. (2017). MA 05.07 Whole Body PD-1 and PD-L1 PET in Pts with NSCLC. Journal of Thoracic Oncology. 12(11). S1817–S1817. 1 indexed citations
18.
Kramer, Gem, Virginie Frings, Nikie J. Hoetjes, et al.. (2015). Repeatability of quantitative uptake measures of whole body [18F]FDG PET/CT in NSCLC patients.. 56. 1379–1379. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masayuki Shirasawa Breakdown of academic impact, for papers by Gee-Chen Chang Breakdown of academic impact, for papers by María José Echarri Breakdown of academic impact, for papers by Yujia Chi Breakdown of academic impact, for papers by Mojca Unk Breakdown of academic impact, for papers by Margaux Geier Breakdown of academic impact, for papers by Ilias Houda Breakdown of academic impact, for papers by Silvana Acquafredda Breakdown of academic impact, for papers by Ina Valeria Zurlo
Rankless by CCL
2026